Patents by Inventor Bibhu Prasad Mishra

Bibhu Prasad Mishra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR CD123 MODIFICATION
    Publication number: 20220333116
    Abstract: This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CD123 gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 20, 2022
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Chonh Luo, Bibhu Prasad Mishra, Michelle Lin
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220259578
    Abstract: Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
    Type: Application
    Filed: January 26, 2022
    Publication date: August 18, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra
  • COMPOSITIONS AND METHODS FOR CD33 MODIFICATION
    Publication number: 20220228153
    Abstract: Some aspects of this disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CD33 gene. Some aspects of the disclosure provide compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 21, 2022
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Bibhu Prasad Mishra
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220211874
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: February 2, 2022
    Publication date: July 7, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-Ching Lin, Bibhu Prasad Mishra, Elizabeth Paik, Andrew Kernytsky, Todd Douglass Borland
  • Materials and methods for treatment of hemoglobinopathies
    Patent number: 11268077
    Abstract: Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: March 8, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210180091
    Abstract: Provided are materials and methods for treating patients with hemoglobinopathies, either ex vivo or in vivo. Also provided are materials and methods for deleting and/or mutating a portion of a human beta globin locus on chromosome 11 and one or more of: a BCL11 A gene on chromosome 2, and a DNA sequence that encodes a transcriptional control region of the BCL11 A gene on chromosome 2, in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF) in the genome-edited human cells.
    Type: Application
    Filed: October 26, 2018
    Publication date: June 17, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra, Chad Albert Cowan, Ante Sven Lundberg, Samarth Kulkarni, Todd Douglass Borland
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20200330609
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 22, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle l-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglass Borland
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190256829
    Abstract: Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
    Type: Application
    Filed: February 5, 2019
    Publication date: August 22, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190201553
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: March 18, 2019
    Publication date: July 4, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglas Borland